Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

867 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 867 results

Large-scale testing (Phase 3)UnknownNCT01093235
What this trial is testing

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Who this might be right for
Breast CancerCardiac ToxicityPerioperative/Postoperative Complications
Cambridge University Hospitals NHS Foundation Trust 800
Post-approval studies (Phase 4)UnknownNCT01597999
What this trial is testing

Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer

Who this might be right for
Invasive Breast Cancer
Mahidol University 60
Testing effectiveness (Phase 2)Study completedNCT02187991
What this trial is testing

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumors+1 more
US Oncology Research 169
Testing effectiveness (Phase 2)Ended earlyNCT04059484
What this trial is testing

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Sanofi 367
Testing effectiveness (Phase 2)Ended earlyNCT00880009
What this trial is testing

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04920708
What this trial is testing

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Who this might be right for
Metastatic Breast CancerER+ Breast CancerAdvanced Breast Cancer
Royal Marsden NHS Foundation Trust 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04975308
What this trial is testing

Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 874
Testing effectiveness (Phase 2)Looking for participantsNCT05837455
What this trial is testing

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 81
Not applicableWithdrawnNCT06978478
What this trial is testing

An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6

Who this might be right for
Breast Cancer
Queen Mary University of London
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Testing effectiveness (Phase 2)Study completedNCT00303524
What this trial is testing

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

Who this might be right for
Breast Cancer
AstraZeneca 170
Testing effectiveness (Phase 2)Study completedNCT01275859
What this trial is testing

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Asan Medical Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT07483307
What this trial is testing

The Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHER2 Negative Breast Carcinoma+2 more
Memorial Sloan Kettering Cancer Center 176
Early research (Phase 1)Study completedNCT04572295
What this trial is testing

E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 51
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Testing effectiveness (Phase 2)Study completedNCT05659563
What this trial is testing

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Who this might be right for
Breast CancerBreast Cancer, Early-Onset
MedSIR 92
Not applicableStudy completedNCT03581552
What this trial is testing

Effects of Aromatase Inhibitor Therapy on Muscle Function

Who this might be right for
Breast CancerBreast Cancer Female
Tarah J Ballinger, MD 16
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757
What this trial is testing

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University 2,934
Testing effectiveness (Phase 2)Study completedNCT02997995
What this trial is testing

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorMenopause+1 more
UNICANCER 61
Next Page